Apotea AB (publ) (STO:APOTEA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 8.14B +3.7% |
| Revenue (ttm) | 7.39B +8.9% |
| Net Income | 236.30M -0.6% |
| EPS | 2.27 -1.6% |
| Shares Out | 104.07M |
| PE Ratio | 34.45 |
| Forward PE | 26.37 |
| Dividend | 0.60 (0.77%) |
| Ex-Dividend Date | n/a |
| Volume | 239,081 |
| Average Volume | 560,302 |
| Open | 78.30 |
| Previous Close | 78.20 |
| Day's Range | 76.30 - 78.40 |
| 52-Week Range | 54.42 - 122.00 |
| Beta | n/a |
| RSI | 74.45 |
| Earnings Date | Apr 17, 2026 |
About Apotea AB
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weigh... [Read more]
Financial Performance
In 2025, Apotea AB's revenue was 7.21 billion, an increase of 10.15% compared to the previous year's 6.54 billion. Earnings were 228.70 million, an increase of 6.42%.
Financial StatementsNews
Apotea AB Earnings Call Transcript: Q1 2026
Q1 delivered 10.5% revenue growth and a 5.2% operating margin, with gross margin at a record 28.3% due to successful campaigns and improved procurement. Growth initiatives included a Norway launch and ramp-up at Varberg, while financial targets remain cautious amid global uncertainties.
Apotea AB Earnings Call Transcript: Q4 2025
Q4 saw 7% revenue growth but weaker profitability due to campaign intensity and Varberg ramp-up costs. Full-year growth was strong at 10.1%, with major investments completed and new growth initiatives underway, including expansion into Norway.
Apotea AB Earnings Call Transcript: Q3 2025
Q3 saw 8.9% revenue growth, a 5% EBIT margin, and strong Rx sales, supported by the successful Varberg warehouse launch and efficiency gains. Net cash reached SEK 98 million, with a focus now shifting to external growth and leveraging new capacity.
Apotea AB Earnings Call Transcript: Q2 2025
Revenue grew 9.9% to SEK 1.826 billion, driven by strong RX demand and stable gross margins. Profitability improved, with an adjusted EBIT margin of 5.4%, and the Varberg facility is set to boost future efficiency. Net cash position remains strong.
Apotea AB Earnings Call Transcript: Q1 2025
Q1 saw 15.2% revenue growth and improved EBIT margin to 5.3%, driven by stable demand and efficiency gains. Preparations for the Varberg fulfillment center are on track, expected to boost capacity by 50%. Guidance remains cautious due to upcoming cost increases and market uncertainties.
Apotea AB Earnings Call Transcript: Q4 2024
Q4 saw 15.8% revenue growth to SEK 1.7 billion, stable margins, and improved profitability, driven by strong Rx sales and automation. Major investments in fulfillment and AI, plus a successful IPO, position the company for further growth and efficiency gains.